Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





Biomarker Detection Platform Configured with MRI System Can Rapidly Screen 100,000 Samples per Day for SARS-CoV-2

By LabMedica International staff writers
Posted on 23 Dec 2020
A breakthrough biomarker detection technology can rapidly detect the SARS-CoV-2 virus and screen more than 100,000 patient specimens per day using standard MRI systems available in hospitals.

Menon Biosensors, Inc. More...
(San Diego, CA, USA) has developed an advanced system and method for detecting the SARS-CoV-2 virus. The system, known as Molecular Mirror, is a detection technique that produces 100% accurate results within 30 minutes of bacterial and viral pathogens tests that at scale could be capable of testing upwards of 100,000 patients per day.

The Molecular Mirror assay achieves high sensitivity and specificity by use of magnetic nanoparticles functionalized with target-specific biomarkers that bind to specific regions of a pathogen's genome. The sample, with bound nanoparticles, is then processed to produce a change in its magnetic properties, specifically the "spin-spin relaxation time," thus producing a signal in the presence of the target of interest, in this case detecting the SARS-CoV-2 virus. This test can be conducted within any MRI machine in the world. The Molecular Mirror assay has achieved 100% detection with no false positives in multiple double-blind tests.

"The Molecular Mirror is a novel, minimal-cost detection platform that enables rapid visualization of an invisible enemy: the SARS-CoV-2 virus. All equipment required for the protocol is readily available in hospital settings. The platform can screen more than 100,000 patient specimens per day per MRI unit. The sensitivity is currently less than 100 viral copies per reaction with 100% specificity. Although technology is currently used in vitro, future application could involve in vivo scanning for various viral and bacterial pathogens," said Dr. Suresh Menon, Founder and President of Menon. "By utilizing existing collection stations and MRI facilities, we could screen the entire population of the US within a day for active cases."

Related Links:
Menon Biosensors, Inc.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.